

Synthesis of 3,5-Diarylisoxazole Derivatives and Evaluation of *in vitro* Trypanocidal Activity

Aline A. N. de Souza,^a Viviane F. Xavier,^{a,b} Gleicekelly S. Coelho,^a
Policarpo A. Sales Junior,^b Alvaro J. Romanha,^b Silvane M. F. Murta,^b
Claudia M. Carneiro^c and Jason G. Taylor^{*,a}

^aDepartamento de Química, Instituto de Ciências Exatas e Biológicas (ICEB),
Universidade Federal de Ouro Preto, Campus Universitário Morro do Cruzeiro,
35400-000 Ouro Preto-MG, Brazil

^bCentro de Pesquisas René Rachou, FIOCRUZ, 30190-002 Belo Horizonte-MG, Brazil

^cLaboratório de Imunopatologia, Núcleo de Pesquisas em Ciências Biológicas (NUPEB),
Universidade Federal de Ouro Preto, Campus Universitário Morro do Cruzeiro,
35400-000 Ouro Preto-MG, Brazil

Chagas disease is included in the neglected tropical diseases list and is endemic to 21 Latin American countries. The two drugs currently available for treating Chagas disease are nifurtimox and benznidazole and both result in many significant side effects. The study describes the synthesis and biological evaluation of 3,5-disubstituted isoxazoles. Isoxazoles were obtained by reaction of flavones and hydroxylamine and either alkylated at the free hydroxyl group and/or nitrated at the isoxazole ring. These compounds were evaluated for their *in vitro* anti-*Trypanosoma cruzi* activity against trypomastigote and amastigote forms of the parasite in *T. cruzi*-infected cell lineages. Benznidazole was used as a reference compound for the *in vitro* assay and mammalian L929 cells were employed to evaluate cytotoxicity. A majority of the compounds tested were very active and the most active isoxazole against amastigote and trypomastigotes of *T. cruzi* was slightly more potent than the current medicine benznidazole.

Keywords: isoxazole, azole, amastigote, trypomastigote, *in vitro*, Chagas disease

Introduction

Discovered by Brazilian scientist Carlos Chagas in 1909,¹ Chagas disease has become endemic to 21 Latin American countries.² The transmission of this disease in humans usually occurs by deposition of faeces contaminated with the protozoan hemoflagellate *Trypanosoma cruzi* after being bitten by the blood-sucking triatomine bugs. Almost half of those infected either have or will develop cardiomyopathy, digestive megasyndromes, or both.³ This “neglected disease” is currently treated in Brazil with benznidazole, but unfortunately, this drug causes many significant side effects.⁴ One of the major problems related to infectious diseases that humanity faces is the continuous mutation that microorganisms suffer and the resistance they develop to medicines. Certain strains of *T. cruzi* have

demonstrated resistance to available drugs.⁵ Different approaches have been taken towards the *in vitro* evaluation of novel synthetic molecules that were tested for anti *T. cruzi* activity. The epimastigote form that is present in the midgut vector has been used for assessing anti-parasitic activity.⁶⁻⁸ The fact that the intracellular amastigotes forms of *T. cruzi* are present in the vertebrate host during the acute and chronic phases of the disease makes the use of this form of the parasite very attractive as screening method for the evaluation of anti *T. cruzi* activity.⁹⁻¹¹ The trypomastigote form enters through the bite wound and is therefore initially present in the blood and, for this reason, the trypomastigote form has also been utilized for *in vitro* screening.¹²⁻¹⁴ Following the guidelines proposed by the Fiocruz Program for Research and Technological Development on Chagas Disease Initiative, the whole cell-based screening methodology was utilized in the present study.^{15,16} This allows us to study the parasite forms that are responsible for

*e-mail: jason@iceb.ufop.br

human infection, analyse novel compounds for anti *T. cruzi* activity in infected cells whilst at the same time monitoring their effects on amastigotes and trypomastigotes in the same system. Differentazole derivatives such as imidazoles,^{9,17} thiazoles,^{12,18} 1,3,4-oxadiazoles,¹⁹ 1,2,4-oxadiazoles²⁰ and 1,2,3-triazoles²¹ have been evaluated for their anti *T. cruzi* activity (Figure 1).

Isioxazoles and their derivatives are considered important heterocyclic compounds due to their prolific biological properties.²² This heterocycle can be encountered in the chemical structure of approved medicines such as Leflunomide, Cloxaciline, Sulfisoxazol, Isocarboxazide, Broxaterole and Sitaxentane amongst others. To the best of our knowledge, isioxazoles have not been explored for their anti *T. cruzi* activity. Motivated by the need to develop more efficient drug candidates for Chagas disease with a less severe side effects profile, we have prepared 17 isioxazole derivatives and tested them against both amastigote and trypomastigote forms of *T. cruzi* *in vitro*.

Results and Discussion

Chemistry

3,5-Diphenylisoxazole **1**, was prepared from chalcone according to literature procedures²³ and used as a reference in order to determine the importance of a free hydroxyl group for anti *T. cruzi* activity (Scheme 1). A major challenge in the synthesis of non-symmetrical 3,5-disubstituted isoxazoles using hydroxylamine is to selectively form one isomer from a substrate that bears two electrophilic centres. The main reactions for obtaining 3,5-diarylisoxazoles

involve the use of chalcones (α - β unsaturated ketones), β -diketones, flavones and cyclocondensation of nitrile oxides with alkynes.²⁴ The key intermediate having 3,5-diarylisoxazole framework were synthesized from flavones²⁵ in four steps (Scheme 1). The synthesis of the target isoxazoles began with the esterification of 2-hydroxyacetophenones with substituted benzoyl chlorides to provide the corresponding esters **2** as illustrated in Scheme 1. A Baker-Venkataraman rearrangement ensued in the presence of KOH to afford 1,3-diketones, which when isolated by precipitation and filtration, were immediately subjected to a condensation reaction under refluxing acetic acid to provide flavones **3**. Many of the ester, 1,3-diketone and flavone intermediates are known compounds and were thus confirmed by comparison of their melting point and nuclear magnetic resonance (NMR) spectral data with literature values. All data for these intermediates were in complete accordance with literature values. Flavones **3** were reacted with hydroxylamine to afford the required isoxazoles **4** in reasonable yields albeit, on occasion, mixtures of isomers were formed. The two isomers were either purified by recrystallization, separated by column chromatography or were immediately subjected to a Williamson type *O*-alkylation reaction to provide the alkylated products **5-9** in good yield. The spectroscopic data of known 3,5-diarylisoxazoles were in accordance with those previously reported. Compounds **5**, **6a-d**, **7a-c**, **8**, **9**, **10** are novel and were therefore characterized by Fourier transform infrared spectroscopy (FTIR), NMR and mass spectrometry (MS).

It has been well documented that benzimidazole and nifurtimox are prodrugs that require nitroreductase





Figure 1. Selected examples ofazole compounds with anti *T. cruzi* activity.



Scheme 1. Synthetic route for the preparation of isoxazole derivatives: (i) NaOH, NH₂OH.HCl, DMSO, 100 °C, 8 h; (ii) pyridine, rt, 1 h; (iii) pyridine, KOH, 50 °C, 1 h; (iv) AcOH, H₂SO₄, reflux, 1 h; (v) NH₂OH.HCl, pyridine, reflux, 14 h; (vi) R₃X (X = Br or I), acetone, K₂CO₃, 60 °C, 18 h.


catalyzed activation within the parasite to have trypanocidal effects. We synthesised a nitro bearing isoxazole for the purpose of evaluating possible enhancement in activity via this known mode of action involving nitroreductase. Compound **9** was nitrated in the presence of acetic anhydride and nitric acid to provide novel compound **10** in 32% yield (Scheme 2).

Biology

Once the final products were purified and fully characterized, we carried out *in vitro* bioassays using trypomastigote and amastigote forms of Tulahuen-strain *T. cruzi*, using the method described by Romanha *et al.*¹⁵ Benznidazole was used as positive control against *T. cruzi* and cytotoxicity was determined in mammalian L929 cells (Table 1).












Our reference compound provided an IC₅₀ (50% inhibitory concentration) of 3.8 μM and gave a selectivity factor (SI) of 625 and was used as a benchmark value for assessing the potency and selectivity of the isoxazole derivatives. Many of the compounds described herein were active at the tested concentrations. A comparison of **1** with **4a** revealed that the presence of the free hydroxyl

group increases potency significantly without rendering the 3,5-diarylisoxazole more cytotoxic. Introducing electron donating groups on to the unsubstituted phenyl ring of **4a** did not result in any remarkable improvements in anti *T. cruzi* activity, but did, however, provide more cytotoxic compounds (compare **4a** to **4b-c**). Completely substituting the benzene ring for a furan moiety **4d** gave similar results to **4b** and **4c**. Next, we evaluated the effect of substituents on the phenol ring and observed almost a doubling in potency with the inclusion of two chlorine atoms (compare **4b** to **4e**). There may not necessarily be any important donor hydrogen bonding interactions associated with the free hydroxyl group of the phenol ring. Indeed, methylation of **4c** afforded compound **5** and a comparison of their *in vitro* activities suggests that potency can be improved when a bulkier substituent in the *ortho* position is present. To test this hypothesis, compounds **6-8** were prepared by benzylation of their corresponding 2-(5-arylisoxazol-3-yl) phenols. In general, the presence of electron withdrawing groups such as fluorine or nitro groups on either aromatic ring gave the best *in vitro* activities and selectivities. In particular, compounds **6b**, **7b** and **8** were the stand out lead compounds and demonstrated very similar anti *T. cruzi* activity to reference compound benznidazole. Narsaiah and



Scheme 2. Nitration of isoxazole **9**: (i) Ac₂O, HNO₃, 0.5 h, 0-5 °C, 32% yield.

Table 1. *In vitro* trypanocidal activity, cytotoxicity and selectivity index of bioactive isoxazoles

| Compound No. | Compound | Trypanocide IC ₅₀ / μM | Cytotoxicity CC ₅₀ / μM | SI | log P | TPSA / Å ² | |
|--------------|---|--|---------------------------------------|------------|-------|-----------------------|-------|
| 1 |  | 53.3 ± 0.9 | 80.0 ± 1.5 | 1.5 | 4.01 | 26.03 | |
| 4a |  | R = H | 33.5 ± 1.0 | 80.0 ± 1.5 | 2.4 | 3.75 | 46.26 |
| 4b | | R = 4-OCH ₃ | 22.8 ± 1.6 | 50.0 ± 4.1 | 2.2 | 3.80 | 55.49 |
| 4c | | R = 3,4,5-(OCH ₃) ₃ | 30.2 ± 1.6 | 55.0 ± 6.1 | 1.8 | 3.38 | 73.96 |
| 4d |  | 26.2 ± 1.5 | 40.0 ± 1.9 | 1.5 | 2.89 | 59.40 | |
| 4e |  | 13.7 ± 1.5 | 10.0 ± 1.0 | 1.4 | 5.06 | 55.49 | |
| 5 |  | 11.7 ± 1.7 | 40.0 ± 4.5 | 3.4 | 3.65 | 62.97 | |
| 6a |  | R = 4-OCH ₃ | 18.0 ± 1.5 | 40.0 ± 5.5 | 2.2 | 5.67 | 44.50 |
| 6b | | R = 4-F | 8.0 ± 1.2 | 45.0 ± 5.0 | 5.6 | 5.78 | 35.27 |
| 6c | | R = 3,4,5-(OCH ₃) ₃ | 25.3 ± 2.2 | 60.0 ± 2.3 | 2.4 | 5.25 | 62.97 |
| 6d |  | inactive | ND | – | 4.51 | 44.50 | |
| 7a |  | R = H | 57 ± 1.9 | 80.0 ± 1.1 | 1.4 | 6.27 | 35.27 |
| 7b | | R = 4-F | 3.3 ± 1.9 | 80.0 ± 5.5 | 26.4 | 6.43 | 35.27 |
| 7c | | R = 4-OCH ₃ | 15 ± 1.3 | 55.0 ± 2.1 | 3.7 | 6.33 | 44.50 |
| 8 |  | 5.9 ± 1.6 | 40.0 ± 1.0 | 6.8 | 5.58 | 90.32 | |
| 9 |  | 18.4 ± 1.0 | 60.2 ± 1.9 | 3.3 | 5.08 | 35.27 | |
| 10 |  | 32.1 ± 1.0 | 73.3 ± 1.0 | 2.3 | 4.96 | 81.09 | |
| Benznidazole | – | 3.8 | 2381 | 625 | – | – | |

IC₅₀: 50% inhibitory concentration; CC₅₀: 50% cytotoxic concentration; ND: not determined; SI: selectivity index calculated from CC₅₀/IC₅₀; TPSA: total polar surface area.

co-workers²⁶ have reported that 5-(3-alkylquinolin-2-yl)-3-aryl isoxazole derivatives screened against four human cancer cell lines (A549, COLO 205, MDA-MB 231 and PC-3) display potent cytotoxicity against all the cell lines at IC₅₀ values of < 12 μM. Given the similarity in chemical structure with isoxazoles **4-9**, the cytotoxicity profile of the compounds described in this report is supported by this literature precedence. As a consequence, the selectivity of the tested compounds was hampered by their cytotoxicity towards mammalian cells. Activation of nitroheterocyclic drugs, such as benzimidazole, by *T. cruzi* has been associated with the formation of reactive radical species responsible for the death of the parasite. For this reason, we synthesised a nitro bearing isoxazole **10** for the purpose of evaluating possible enhancement in activity via this known mode of action. Surprisingly, both anti *T. cruzi* activity and cytotoxicity were lower than the parent compound **9** and this result suggests that nitro-isoxazoles are not activated by nitroreductase like their imidazole (benzimidazole) and furan (nifurtimox) counterparts. The physicochemical drug descriptors of the molecular properties for the synthesized compounds were calculated by Molinspiration software.²⁷ The partition coefficient (log P: octanol/water partition coefficient) describes the equilibrium distribution between two liquid phases such as octanol and water and the total polar surface area (TPSA) is a measure of the extent of the molecules exposed polar area. No linear correlations between hydrophobicity and bioactivity were observed. On the other hand, all log P values for the most bioactive compounds were found to be slightly greater than **5** (Lipinski's rule of five). The largest TPSA values were all below the limit of 140 Å² (Lipinski's rule of five); based on the TPSA value alone, the most potent compounds, **6b** and **7b**, would be expected to perform better in permeating the parasites cell membranes. Thus, these results suggest that penetration of cell membranes is not the critical factor determining anti *T. cruzi* activity.

Conclusions

In conclusion, although the potency of many of the isoxazole derivatives was less active than the positive control, anti *T. cruzi* activity was significantly improved by the inclusion of fluorine group on to either the phenol of phenyl ring of the 3,5-diarylisoxazole. In one case, the isoxazole derivative **7b** was slightly more potent than benzimidazole. Further studies and investigations by colorimetric methods and indirect analysis by light microscopy are ongoing in order to discern the mechanism of action of the most potent lead compounds uncovered in the present study.

Experimental

All commercial reagents were used as received. Anhydrous solvents were purchased from Sigma-Aldrich. Flash column chromatography was performed using silica gel 200-400 mesh. Thin layer chromatography (TLC) analysis were performed using silica gel plates, using ultraviolet (UV) light (254 nm), phosphomolybdic acid or vanillin solution for visualization. Melting points are uncorrected and were recorded on a Buchi B-540 apparatus. For NMR data, the chemical shifts are reported in δ (ppm) referenced to residual solvent protons and ¹³C signals in deuterated chloroform. Coupling constants (*J*) are expressed in hertz (Hz). Infrared spectra were obtained on a Thermo Scientific Nicolet 380 FT-IR apparatus (600-4000 cm⁻¹, Nicolet Instrument Corp., Madison, WI, USA) using attenuated total reflection (ATR). Mass spectra were obtained by GC-MS, Shimadzu QP-2010 Plus model (Shimadzu, Kyoto, Japan) and high resolution mass spectra (HRMS) were obtained on a Shimadzu HPLC-ESI-IT-TOF. SMILES notations of the isoxazole derivatives were inputted into the online Molinspiration software (software version v2015.01)²⁷ and subjected to molecular properties prediction by Molinspiration software. Flavones were prepared according to literature methods.²⁵

Typical experimental procedure for the synthesis of isoxazoles **4-10**

In a round bottom flask (50.0 mL) equipped with stir bar and reflux condenser was added flavone (2.0 mmol), pyridine (10.0 mL) and hydroxylamine hydrochloride (6.0 mmol). The reaction was stirred at 100 °C for 14 h. The reaction was then allowed to cool to room temperature and poured in an ice-water mixture (20.0 mL). The precipitate that formed was filtered and recrystallized from ethanol. A selection of certain isoxazoles were alkylated with either iodomethane, iodoethane or benzylbromide as follows: in a round bottom flask (50.0 mL) equipped with stir bar and reflux condenser were added isoxazole (1.0 mmol), anhydrous K₂CO₃ (2.0 mmol) and acetone (20.0 mL) at 0 °C. Next, the alkylhalide (1.5 mmol) was added slowly at 0 °C with stirring and the reaction was then warmed to 60 °C and allowed to stir at this temperature overnight. Upon completion, the reaction mixture was cooled to room temperature, concentrated under reduced pressure and then taken up in to a separatory funnel containing ethyl acetate (20.0 mL). The organic layer was washed with distilled water (15.0 mL) and the organic phases were worked up in the usual way. An oily residue was obtained and purified by flash chromatography eluted

in a gradient mixture of hexanes and ethyl acetate (1-10% ethyl acetate in hexanes).

2-(3-Phenylisoxazol-5-yl) phenol (**4a**)

Product obtained as a white solid in 47% yield; mp 221-222 °C (Lit.¹² mp 232-236 °C); R_f (retention factor) = 0.5 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 3402, 1614, 1456, 950, 756, 684; ^1H NMR (300 MHz, DMSO) δ 6.91-7.65 (m, 7H), 7.82-8.01 (m, 3H), 10.06 (s, 1H); ^{13}C NMR (75 MHz, DMSO) δ 101.3, 114.6, 115.1, 117.2, 120.2, 121.9, 127.5, 128.8, 132.1, 155.4, 161.3, 162.6, 167.0; EI (electron ionization) m/z : 237 (25%), 207 (20%), 117 (100%), 73 (90%), 63 (77%); HRMS (ESI, electrospray ionization) m/z : $[\text{M} + \text{H}]^+$ calcd. for $\text{C}_{15}\text{H}_{12}\text{NO}_2$: 238.0868; found: 238.0782.

2-(3-(4-Methoxyphenyl)isoxazol-5-yl)phenol (**4b**)

Product obtained as a yellow solid in 78% yield. mp 208-210 °C (Lit.²⁸ mp 212-214 °C); R_f = 0.4 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 3200, 1600, 1500, 1450, 1260, 1030; ^1H NMR (400 MHz, DMSO) δ 3.80 (s, 3H), 7.00 (t, J 8.4 Hz, 1H), 7.04-7.08 (m, 3H), 7.30 (s, 1H), 7.33 (d, J 8.4 Hz, 1H), 7.79 (d, J 7.8 Hz, 1H), 7.90 (d, J 9.0 Hz, 2H); ^{13}C NMR (100 MHz, DMSO) δ 55.9, 101.3, 114.6, 115.1, 117.2, 120.2, 121.9, 127.5, 128.8, 132.1, 155.4, 161.3, 162.6, 167.0; EI m/z : 267 (15%), 252 (10%), 236 (30%), 108 (100%); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd. for $\text{C}_{16}\text{H}_{14}\text{NO}_3$: 268.0974; found: 268.0967.

2-(3-(3,4,5-Trimethoxyphenyl)isoxazol-5-yl)phenol (**4c**)

Product obtained as a white solid in 82% yield; mp 218-219 °C (Lit.²⁹ mp 235-238 °C); R_f = 0.3 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 3160, 1600, 1500, 1420, 1250, 1010; ^1H NMR (400 MHz, DMSO) δ 3.70 (s, 3H), 3.90 (s, 6H), 6.95 (t, J 7.5 Hz, 1H), 7.10 (d, J 8.4 Hz, 1H), 7.20 (s, 2H), 7.31-7.42 (m, 2H), 7.81 (d, J 8.4 Hz, 1H), 10.65 (brs, 1H); ^{13}C NMR (100 MHz, DMSO) δ 56.8, 60.8, 101.8, 104.7, 114.6, 117.2, 120.2, 125.0, 127.6, 132.2, 139.6, 154.0, 155.4, 163.0, 167.3; EI m/z : 327 (5%), 312 (20%), 296 (10%), 170 (35%), 93 (100%); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd. for $\text{C}_{18}\text{H}_{18}\text{NO}_5$: 328.1185; found: 328.1191.

2-(3-(Furan-2-yl)isoxazol-5-yl)phenol (**4d**)

Product obtained as a white solid in 55% yield; mp 198-199 °C (Lit.³⁰ mp 237-239 °C); R_f = 0.5 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 3120, 1600, 1500, 1370, 1240, 960; ^1H NMR (500 MHz, DMSO) δ 6.71-6.72 (m, 1H), 7.0 (t, J 8.0 Hz, 1H), 7.10 (d, J 8.0 Hz, 1H), 7.21-7.23 (m, 2H), 7.40 (t, J 8.5 Hz, 1H), 7.80 (d, J 8.0 Hz, 1H), 7.90 (brs, 1H), 10.70 (s, 1H, OH); ^{13}C NMR (125 MHz, DMSO)

δ 100.7, 111.8, 112.5, 114.0, 117.0, 119.9, 127.3, 132.1, 144.2, 145.3, 155.2, 155.3, 166.8; EI m/z : 227 (55%), 121 (100%), 105 (70%), 65 (90%); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd. for $\text{C}_{13}\text{H}_{10}\text{NO}_3$: 228.0661; found: 228.0656.

2,4-Dichloro-6-(3-(4-methoxyphenyl)isoxazol-5-yl)phenol (**4e**)

Product obtained as a white solid in 47% yield; mp 206-208 °C (Lit.³¹ mp 193 °C); R_f = 0.4 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 1701, 1359, 1224, 536; ^1H NMR (400 MHz, DMSO) δ 3.80 (s, 3H), 7.10 (d, J 8.8 Hz, 2H), 7.40 (s, 1H); 7.70 (d, J 8.4 Hz, 1H), 7.80 (d, J 8.4 Hz, 1H), 7.90 (d, J 8.8 Hz, 2H); ^{13}C NMR (100 MHz, DMSO) δ 55.8, 102.8, 115.0, 118.7, 121.2, 123.9, 124.4, 125.9, 128.6, 130.9, 149.8, 161.3, 162.6, 165.0; EI m/z : 335 (10%), 108 (100%); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd. for $\text{C}_{16}\text{H}_{12}\text{Cl}_2\text{NO}_3$: 336.0194; found: 336.0200.

5-(2-Methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)isoxazole (**5**)

Product obtained as a white solid in 72% yield; mp 88-92 °C; R_f = 0.5 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 1600, 1500, 1460, 1240, 1120; ^1H NMR (500 MHz, CDCl_3) δ 3.90 (s, 3H), 4.00 (s, 6H), 4.05 (s, 3H), 7.06-7.15 (m, 5H), 7.45-7.48 (m, 1H), 8.05 (d, J 7.5 Hz, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 55.7, 56.4, 61.0, 101.4, 104.3, 111.3, 116.5, 121.0, 125.0, 127.8, 131.3, 139.6, 153.6, 156.2, 162.9, 166.5; EI m/z : 341 (100%), 326 (50%), 135 (90%); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd. for $\text{C}_{19}\text{H}_{20}\text{NO}_5$: 342.1341; found: 342.1333.

5-(2-(Benzyloxy)phenyl)-3-(4-methoxyphenyl)isoxazole (**6a**)

Product obtained as a yellow solid in 62% yield; mp 95-98 °C; R_f = 0.6 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 2925, 1608, 1512, 1458, 1249; ^1H NMR (400 MHz, CDCl_3) δ 3.90 (s, 3H), 5.30 (s, 2H), 7.00 (d, J 9.2 Hz, 2H), 7.06 (s, 1H), 7.10-7.16 (m, 2H), 7.40-7.50 (m, 4H), 7.55 (d, J 8.4 Hz, 2H), 7.70 (d, J 8.8 Hz, 2H), 8.10 (d, J 7.6 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 55.4, 70.7, 101.6, 112.6, 114.2, 117.0, 121.2, 122.1, 127.7, 127.8, 128.1, 128.4, 128.7, 131.0, 136.4, 155.3, 160.8, 162.5, 166.0; EI m/z : 357 (10%), 91 (100%); HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd. for $\text{C}_{23}\text{H}_{20}\text{NO}_3$: 358.1443; found: 358.1488.

5-(2-(Benzyloxy)phenyl)-3-(4-fluorophenyl)isoxazole (**6b**)

Product obtained as a white solid in 27% yield; mp 145-148 °C; R_f = 0.66 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 1500, 1442, 1236, 754, 698; ^1H NMR (400 MHz, CDCl_3) δ 5.30 (s, 2H), 7.05 (s, 1H), 7.11-7.17 (m, 4H), 7.40-7.55 (m, 6H), 7.75-7.80 (m, 2H), 8.10 (d, J 7.6 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 70.8, 101.6, 112.6,

116.0 (d, J_{C-F} 11 Hz), 116.7, 121.3, 125.7 (d, J_{C-F} 3 Hz), 127.7, 127.8, 128.4, 128.5 (d, J_{C-F} 9 Hz), 128.8, 131.2, 136.3, 155.4, 162.1, 163.7 (d, J_{C-F} 248 Hz), 166.4; EI m/z : 345 (10%), 91 (100%); HRMS (ESI) m/z : $[M + H]^+$ calcd. for $C_{22}H_{17}FNO_2$: 346.1243; found: 346.1231.

5-(2-(Benzyloxy)phenyl)-3-(3,4,5-trimethoxyphenyl)isoxazole (**6c**)

Product obtained as a white solid in 78% yield; mp 148-153 °C; R_f = 0.5 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 1600, 1500, 1450, 1140, 1000; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 3.86 (s, 6H), 3.88 (s, 3H), 5.20 (s, 2H), 6.90-7.01 (m, 2H), 7.11-7.16 (m, 2H), 7.37-7.46 (m, 4H), 7.55 (d, J 7.2 Hz, 2H), 8.03 (d, J 7.8 Hz, 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 56.1, 60.9, 70.7, 101.7, 103.8, 112.3, 116.6, 121.2, 124.8, 127.7, 128.2, 128.3, 128.7, 131.2, 136.3, 139.4, 153.5, 155.4, 162.7, 166.2; EI m/z : 312 (100%), 297 (50%); HRMS (ESI) m/z : $[M + H]^+$ calcd. for $C_{25}H_{24}NO_5$: 418.1654; found: 418.1649.

5-(2-(Benzyloxy)phenyl)-3-(furan-2-yl)isoxazole (**6d**)

Product obtained as a white solid in 60% yield; mp 122-123 °C; R_f = 0.34 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 1600, 1400, 1400, 1260, 1020; $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 5.30 (s, 2H), 6.53-6.55 (m, 1H), 6.80 (d, J 3.2 Hz, 1H), 7.10 (s, 1H), 7.15-7.40 (m, 2H), 7.48-7.51 (m, 4H), 7.56 (d, J 8.8 Hz, 2H), 7.57 (brs, 1H), 8.10 (d, J 7.60 Hz, 1H); $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 70.7, 101.2, 110.0, 111.6, 112.6, 116.6, 121.2, 127.5, 128.0, 128.3, 128.7, 131.3, 136.3, 143.7, 144.8, 155.4, 155.4, 166.0; EI m/z : 317 (10%), 91 (100%); HRMS (ESI) m/z : $[M + H]^+$ calcd. for $C_{20}H_{16}NO_3$: 318.1130; found: 318.1123.

5-(2-(Benzyloxy)-5-chlorophenyl)-3-phenylisoxazole (**7a**)

Product obtained as a white solid in 79% yield; mp 196-196 °C; R_f = 0.34 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 1600, 1400, 1360, 1240, 1020; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 5.20 (s, 2H), 7.0 (d, J 8.7 Hz, 1H), 7.10 (s, 1H), 7.33-7.36 (d, J 2.4, 9.0 Hz, 1H), 7.43-7.47 (m, 8H), 7.74-7.77 (m, 2H), 8.0 (d, J 2.40 Hz, 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 70.1, 102.5, 113.8, 118.1, 126.4, 126.7, 127.4, 127.6, 128.5, 128.8, 128.8, 129.2, 129.9, 130.6, 135.8, 153.8, 163.0, 164.9; EI m/z : 361 (5%), 91 (100%), HRMS (ESI) m/z : $[M + H]^+$ calcd. for $C_{22}H_{17}ClNO_2$: 362.0948; found: 362.0965.

5-(2-(Benzyloxy)-5-chlorophenyl)-3-(4-fluorophenyl)isoxazole (**7b**)

Product obtained as a white solid in 85% yield; mp 192-193 °C; R_f = 0.3 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 1600, 1500, 1440, 1260, 1240, 1020, 740; $^1\text{H NMR}$

(300 MHz, CDCl_3) δ 5.20 (s, 2H), 7.00 (s, 2H), 7.10 (d, J 8.7 Hz, 2H), 7.32-7.35 (dd, J 9.0, 2.4 Hz, 1H), 7.40-7.47 (m, 5H), 7.68-7.72 (m, 2H), 8.0 (d, J 2.40 Hz, 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 71.1, 102.3, 113.9, 116.1 (d, J_{C-F} 21.75 Hz), 117.8, 126.4, 127.4, 127.6, 128.5 (d, J_{C-F} 1.5 Hz), 128.6, 128.8, 130.8, 135.8, 153.8, 162.7, 162.1, 165.1, 165.4; EI m/z : 379 (15%), 120 (25%), 91 (100%), HRMS (ESI) m/z : $[M + H]^+$ calcd. for $C_{22}H_{16}ClFO_2$: 380.0854; found: 380.0853.

5-(2-(Benzyloxy)-5-chlorophenyl)-3-(4-methoxyphenyl)isoxazole (**7c**)

Product obtained as a white solid in 32% yield; mp 174-174 °C; R_f = 0.4 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 1600, 1500, 1360, 1250, 1020, 710; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 3.90 (s, 3H), 5.20 (s, 2H), 6.90-7.00 (m, 4H), 7.30-7.33 (dd, J 2.4, 9.0 Hz, 1H), 7.40-7.50 (m, 5H), 7.70 (d, J 8.1 Hz, 2H), 8.00 (d, 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 55.3, 71.1, 102.3, 113.8, 114.2, 118.1, 121.7, 126.4, 127.4, 127.7, 128.1, 128.5, 128.8, 130.5, 135.0, 153.7, 160.9, 162.6, 164.6; EI m/z : 391 (20%), 108 (25%), 91 (100%); HRMS (ESI) m/z : $[M + H]^+$ calcd. for $C_{23}H_{19}ClNO_3$: 392.1053; found: 392.1044.

5-(2-(Benzyloxy)-5-methoxyphenyl)-3-(3-nitrophenyl)isoxazole (**8**)

Product obtained as a white solid in 63% yield; mp 150-152 °C; R_f = 0.30 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 1600, 1500, 1360, 1230, 1070; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 3.90 (s, 3H), 5.30 (s, 2H), 7.0 (d, J 9.6 Hz, 1H), 7.10 (s, 1H), 7.30 (d, J 9.0 Hz, 1H), 7.33-7.43 (m, 4H), 7.50 (d, J 7.8 Hz, 2H), 7.60 (t, J 8.1 Hz, 1H), 8.10 (d, J 8.7 Hz, 1H), 8.30 (d, J 9.0 Hz, 1H), 8.70 (s, 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 55.8, 76.4, 94.8, 104.4, 118.6, 118.7, 119.3, 120.6, 124.5, 127.9, 128.3, 128.4, 129.7, 131.2, 134.7, 138.0, 143.4, 146.0, 148.5, 152.3, 156.7; EI m/z : 402 (5%), 91 (100%); HRMS (ESI) m/z : $[M + H]^+$ calcd. for $C_{23}H_{19}N_2O_5$: 403.1294; found: 403.1314.

5-(4-Chlorophenyl)-3-(2-ethoxyphenyl)isoxazole (**9**)

Product obtained as a white solid in 57% yield; mp 142-144 °C; R_f = 0.38 (ethyl acetate/hexane 3:7); IR (ATR) ν / cm^{-1} 1600, 1500, 1460, 1240, 1120; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.56 (t, J 6.0 Hz, 3H), 4.22 (q, J 6.0 Hz, 2H), 7.00-7.11 (m, 3H), 7.38-7.47 (m, 3H), 7.80 (d, J 9.0 Hz, 2H), 8.02 (d, J 6.0 Hz, 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 14.8, 64.1, 101.2, 111.9, 116.2, 120.8, 126.0, 127.7, 128.1, 129.1, 131.3, 135.7, 155.6, 161.9, 166.7; EI m/z : 299 (30%), 113 (10%), 77 (15%); HRMS (ESI) m/z : $[M + H]^+$ calcd. for $C_{17}H_{15}ClNO_2$: 300.0791; found: 300.0831.

Nitration of isoxazole 9

Synthesis of 3-(4-chlorophenyl)-5-(2-ethoxyphenyl)-4-nitroisoxazole (10)

To a suspension of isoxazole **10** (230 mg, 0.69 mmol) in Ac₂O (7 mL) was added dropwise concentrated HNO₃ (0.05 mL) at 0 °C with stirring. A temperature range of 0 and 5 °C was maintained until addition of nitric acid was complete. Next, the reaction mixture was stirred for 70 h at room temperature and then poured into ice (25 mL) and extracted with dichloromethane (3 × 20 mL). The organic extracts was dried with sodium sulfate, filtered and concentrated under vacuum. The yellow solid obtained was triturated with Et₂O, filtered and then purified by column chromatography (ethyl acetate/hexane 1:9) to yield **10** as a pale yellow solid in 32% yield; mp 193-194 °C; R_f = 0.36 (ethyl acetate/hexane 1:9); IR (ATR) ν / cm⁻¹ 1504, 1429, 1346, 1286, 1089, 709; ¹H NMR (300 MHz, CDCl₃) δ 1.67 (t, *J* 6.0 Hz, 3H), 4.39 (q, *J* 6.0 Hz, 2H), 7.10-7.07 (m, 2H), 7.47 (d, *J* 9.0 Hz, 2H), 7.80 (d, *J* 9.0 Hz, 2H), 8.30 (dd, *J* 9.0, 3.0 Hz, 1H), 8.89 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 14.6, 65.6, 102.6, 111.9, 116.7, 123.6, 126.7, 127.4, 128.0, 129.2, 136.1, 141.1, 159.7, 162.2, 164.3; EI *m/z*: 344 (5%), HRMS (ESI) *m/z*: [M + H]⁺ calcd. for C₁₇H₁₄ClN₂O₄: 345.0642; found: 345.0654.

Anti-*Trypanosoma cruzi* activity assay

The *in vitro* anti-*T. cruzi* activity was evaluated on L929 cells (mouse fibroblasts) infected with Tulahuen strain of the parasite expressing the *Escherichia coli* β -galactosidase as reporter gene according to the method described previously.¹⁵ Briefly, for the bioassay, 4,000 L929 cells were added to each well of a 96-well microtiter plate. After an overnight incubation, 40,000 trypomastigotes were added to the cells and incubated for 2 h. Then the medium containing extracellular parasites was replaced with 200 μ L of fresh medium and the plate was incubated for an additional 48 h to establish the infection. For IC₅₀ determination, the cells were exposed to each synthesized compound at serial decreasing dilutions and the plate was incubated for 96 h. After this period, 50 μ L of 500 μ M chlorophenol red beta-D-galactopyranoside (CPRG) in 0.5% Nonidet P40 was added to each well, and the plate was incubated for 16 to 20 h, after which the absorbance at 570 nm was measured. Controls with uninfected cells, untreated infected cells, infected cells treated with benznidazole at 3.8 μ M (positive control) or DMSO 1% were used. The results were expressed as the percentage of *T. cruzi* growth inhibition in compound-tested cells as compared to the infected cells and untreated cells. The IC₅₀ values were calculated by linear

interpolation. Quadruplicates were run in the same plate, and the experiments were repeated at least once.

Supplementary Information

Supplementary information and NMR spectra are available free of charge at <http://jbcs.sbq.org.br> as PDF file.

Acknowledgments

This work was supported by the Brazilian funding agency Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) under research grant project code APQ-01629-16. Authors gratefully acknowledge the generous financial support from the Universidade Federal de Ouro Preto (UFOP), FAPEMIG and the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). The authors thank the Program for Technological Development of Tools for Health-PDTIS-FIOCRUZ for use of its facilities. The authors would also like to thank Prof Dr Robson Jose de Cassia Afonso (UFOP) and Ananda Lima Sanson (UFOP) for the excellent mass spectrometry service.

References

1. Chagas, C.; *Mem. Inst. Oswaldo Cruz* **1909**, *1*, 159.
2. Hotez, P. J.; Dumonteil, E.; Woc-Colburn, L.; Serpa, J. A.; Bezek, S.; Edwards, M. S.; Hallmark, C. J.; Musselwhite, L. W.; Flink, B. J.; Bottazzi, M. E.; *PLoS Neglected Trop. Dis.* **2012**, *6*, 1498.
3. Junior, A. R.; Rassi, A.; Marin-Neto, J. A.; *J. Chem. Res.* **2010**, 375, 1388.
4. Bermudez, J.; Davies, C.; Simonazzi, A.; Real, J. P.; Palma, S.; *Acta Trop.* **2016**, *156*, 1.
5. Wilkinson, S. R.; Kelly, J. M.; *Expert Rev. Mol. Med.* **2009**, *11*, 31.
6. Tapia, R. A.; Salas, C. O.; Vázquez, K.; Espinosa-Bustos, C.; Soto-Delgado, J.; Varela, J.; Birriel, E.; Cerecetto, H.; González, M.; Paulino, M.; *Org. Synth.* **2014**, *24*, 3919.
7. Menezes, J. C.; Vaz, L. B.; Vieira, P. M. A.; Fonseca, K. S.; Carneiro, C. M.; Taylor, J. G.; *Molecules* **2014**, *20*, 43.
8. Moreira, D. R.; Leite, A. C. L.; Cardoso, M. V.; Srivastava, R. M.; Hernandez, M. Z.; Rabello, M. M.; da Cruz, L. F.; Ferreira, R. S.; de Simone, C. A.; Meira, C. S.; Guimaraes, E. T.; *Chem. Med. Chem.* **2014**, *9*, 177.
9. Olmo, F.; Gómez-Contreras, F.; Navarro, P.; Marín, C.; Yunta, M. J.; Cano, C.; Campayo, L.; Martín-Oliva, D.; Rosales, M. J.; Sánchez-Moreno, M.; *Eur. J. Med. Chem.* **2015**, *106*, 106.
10. Gómez-Ayala, S.; Castrillón, J. A.; Palma, A.; Leal, S. M.; Escobar, P.; Bahsas, A.; *Bioorg. Med. Chem.* **2010**, *18*, 39.

11. Caputto, M. E.; Ciccarelli, A.; Frank, F.; Moglioni, A. G.; Moltrasio, G. Y.; Vega, D.; Lombardo, E.; Finkielstein, L. M.; *Eur. J. Med. Chem.* **2012**, *55*, 63.
12. Cardoso, M. V. O.; de Siqueira, L. R.; da Silva, E. B.; Costa, L. B.; Hernandez, M. Z.; Rabello, M. M.; Ferreira, R. S.; da Cruz, L. F.; Moreira, D. R.; Pereira, V. R.; de Castro, M. C.; *Eur. J. Med. Chem.* **2014**, *86*, 48.
13. da Silva, R. B.; Loback, V. B.; Salomão, K.; de Castro, S. L.; Wardell, J. L.; Wardell, S. M.; Costa, T. E.; Penido, C.; de Henriques, M. D.; Carvalho, S. A.; da Silva, E. F.; *Molecules* **2013**, *18*, 57.
14. Soares, F. A.; Sesti-Costa, R.; da Silva, J. S.; de Souza, M. C.; Ferreira, V. F.; Santos, F. D.; Monteiro, P. A.; Leitao, A.; Montanari, C. A.; *Bioorg. Med. Chem.* **2013**, *23*, 4597.
15. Romanha, A. J.; Castro, S. L.; Soeiro, M. D.; Lannes-Vieira, J.; Ribeiro, I.; Talvani, A.; Bourdin, B.; Blum, B.; Olivieri, B.; Zani, C.; Spadafora, C.; *Mem. Inst. Oswaldo Cruz* **2010**, *105*, 233.
16. Elias, P. R.; Coelho, G. S.; Xavier, V. F.; Sales Junior, P. A.; Romanha, A. J.; Murta, S. M. F.; Carneiro, C. M.; Camilo, N. S.; Hilário, F. F.; Taylor, J. G.; *Molecules* **2016**, *21*, 1342.
17. Papadopoulou, M. V.; Bloomer, W. D.; Rosenzweig, H. S.; Wilkinson, S. R.; Kaiser, M.; *Eur. J. Med. Chem.* **2014**, *87*, 79.
18. Gomes, P. A. M.; Oliveira, A. R.; Cardoso, M. V. O.; Santiago, E. F.; Barbosa, M. O.; de Siqueira, L. R.; Moreira, D. R.; Bastos, T. M.; Brayner, F. A.; Soares, M. B.; Mendes, A. P. O.; *Eur. J. Med. Chem.* **2016**, *111*, 46.
19. Ishii, M.; Jorge, S. D.; de Oliveira, A. A.; Palace-Berl, F.; Sonehara, I. Y.; Pasqualoto, K. F.; Tavares, L. C.; *Bioorg. Med. Chem.* **2011**, *19*, 301.
20. dos Santos Filho, J. M.; Leite, A. C.; de Oliveira, B. G.; Moreira, D. R.; Lima, M. S.; Soares, M. B.; Leite, L. F.; *Bioorg. Med. Chem.* **2009**, *17*, 91.
21. de Andrade, P.; Galo, O. A.; Carvalho, M. R.; Lopes, C. D.; Carneiro, Z. A.; Sesti-Costa, R.; de Melo, E. B.; Silva, J. S.; Carvalho, I.; *Bioorg. Med. Chem.* **2015**, *23*, 26.
22. Chakroborty, S.; Bhanja, C.; Jena, S.; *Heterocycl. Commun.* **2013**, *19*, 79.
23. Li, Z.; Wen, G.; Fu, R.; Yang, J.; *J. Chem. Res.* **2016**, *40*, 643.
24. For a recent review see: Galenko, A. V.; Khlebnikov, A. F.; Novikov, M. S.; Pakalnis, V. V.; Rostovskii, N. V.; *Russ. Chem. Rev.* **2015**, *84(4)*, 335.
25. Wheeler, T. S.; *Org. Synth.* **1952**, 72.
26. Rao, P. S.; Kurumurthy, C.; Veeraswamy, B.; Poornachandra, Y.; Kumar, C. G.; Narsaiah, B.; *Bioorg. Med. Chem. Lett.* **2014**, *24(5)*, 1349.
27. Molinspiration Cheminformatics, v2015.01, Bratislava University, Slovak Republic, 1986. Available at <http://www.molinspiration.com/>, accessed on September 20, 2016.
28. Livingston, M. J.; Chick, M. F.; Shealy, E. O.; Beam, C. F.; *J. Heterocycl. Chem.* **1982**, *19*, 215.
29. Patonay, T.; Bogann, R.; *Tetrahedron* **1984**, *40*, 2555.
30. Gothelf, K. V.; Torrsell, K. B. G.; *Acta Chem. Scand.* **1994**, *48*, 61.
31. Shah, M.; Patel, P.; Korgaokar, S.; Parekh, H.; *Indian J. Chem.* **1996**, *35*, 1282.

Submitted: April 1, 2017

Published online: July 13, 2017